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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
Dabigatran is superior to Warfarin in patients with atrial fibrillation. 
 
STUDY DESIGN: Review of three English language primary studies published in 2007, 
2009, and 2010.  
 
DATA SOURCES: Three randomized control trials found using Cochrane Database.  
 
OUTCOME(S) MEASURED: Outcomes measured were presence or absence of stroke or 
systolic embolism and intracranial hemorrhage. The absence of these events preserved 
neurologic function in patients with atrial fibrillation.  
 
RESULTS: In both VKA-naïve and VKA-experienced patients, Dabigatran 150 mg was 
superior to Warfarin in both the prevention of stroke and systolic embolism and the 
prevention of intracranial hemorrhage. Thromboembolic events were most common in 
the group receiving Dabigatran 50 mg alone. When comparing Dabigatran and Warfarin 
without including previous VKA status, Dabigatran 150 mg is superior to Warfarin in 
prevention of stroke and systolic embolism, while Dabigatran 110 mg is noninferior. 
Hemorrhagic stroke rates were similar in both dose groups.   
 
CONCLUSIONS: It is concluded that Dabigatran is superior to Warfarin in 150 mg dose 
and noninferior to Warfarin in 110 mg dose. Further research is warranted to determine 
other indications for treatment with Dabigatran.   
 
KEY WORDS: Dabigatran, Warfarin, atrial fibrillation, stroke 
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INTRODUCTION 
 
 Atrial fibrillation is the most common chronic cardiac arrhythmia, affecting 10% 
of people over age 80 years. However, because atrial fibrillation is commonly 
asymptomatic, it is estimated that actual incidence rates may be double the reported rate6. 
It is estimated that the annual cost of treating atrial fibrillation is $26 billion5. About 350,000	  hospitalizations,	  5.0	  million	  office	  visits,	  276,000	  ED	  visits	  and	  234,000	  OPD	  annually	  in	  the	  United	  States	  are	  attributed	  to	  atrial	  fibrillation2.  
Atrial fibrillation may occur without cardiac disease or in the presence of valvular 
heart disease, dilated cardiomyopathy, hypertension, or coronary heart disease. It may 
also have an acute, direct cause such as hyperthyroidism or alcohol intoxication. It is 
much more common in adults and very rare in children. Cases in children are typically 
due to congenital cardiac abnormalities such as WPW syndrome6.  
Atrial fibrillation is a condition in which there is rapid, irregular atrial activation 
with irregular ventricular response. The rate is usually between 120-160 bpm, but can be 
as high as >200 bpm6. The cause of atrial fibrillation remains commonly debated, but 
appears to be related to the complex interaction between the drivers of electrical impulse 
and the complex that potentiates the maintenance of wavelets of reentry6. Atrial 
fibrillation is significant clinically because it is related to the loss of atrial contractility, 
results in inappropriate fast ventricular response, and the loss of atrial contractility and 
emptying results in the risk of clot formation and subsequent thromboembolic events6. 
For many years, Warfarin was the gold standard treatment in prevention of 
thromboembolic events in patients with atrial fibrillation. Warfarin with an international 
normalized ratio (INR) of 2.0-3.0 has been recommended for patients with frequent or 
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sustained AF or with risk factors for thromboembolism. These risk factors include age > 
65, history of congestive heart failure, diabetes mellitus, hypertension, left ventricular 
dysfunction, and left atrial enlargement6.  
Dabigatran is a direct thrombin inhibitor with a half-life of 12-17 hours. It does 
not require serum monitoring as Warfarin does. It was evaluated in a pilot trial of patients 
with atrial fibrillation with a goal of preventing venous thromboembolism. The results 
were found to be promising and Dabigatran was subsequently explored further as an 
alternative treatment for patients with nonvalvular atrial fibrillation1.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not 
Pradaxa (Dabigatran) is a more effective treatment of atrial fibrillation than Warfarin.  
METHODS 
 The studies included in this selective EBM review involved patients over 65 years 
old with atrial fibrillation, LVEF<40%, heart failure, and some variation of CAD. 
Exclusion criteria included valvular disorders, kidney or liver dysfunction, pregnancy, 
and recent stroke. The intervention of Dabigatran 50, 110, 150, or 300 mg was compared 
against Warfarin titrated to a therapeutic INR level of 2.0-3.0. Outcome measured is 
preservation of neurologic function in patients with atrial fibrillation. This outcome is 
measured by rates of stroke or systolic embolism and intracranial hemorrhage in these 
patients. Studies compared are randomized controlled trials that are double-blinded with 
Dabigatran and open label with Warfarin out of necessity. 
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 Table 1: Demographics & Characteristics of Included Studies 
Study	  
Study	   Type	  	   #	  pts	   Age	  (yrs)	   Inclusion	  Criteria	   Exclusion	  Criteria	   W/D	   Interventions	  Type	  	   #	  pts	   Age	  (yrs)	   Inclusion	  Criteria	   Exclusion	  Criteria	   W/D	   Interventions	  Connolly	  (2009)	   RCT	   18,113	   >65	   -­‐Prev	  CVA/TIA	  -­‐LVEF	  <40%	  >Class	  II	  HF	  sx	  within	  6	  months	  -­‐Age	  >75	  or	  65-­‐74	  plus	  DM,	  HTN,	  or	  CAD	  
o 	  
-­‐valvular	  disorder	  -­‐recent	  stroke	  -­‐increased	  hemorrhage	  risk	  -­‐CCl<30	  ml/min	  -­‐liver	  disease	  -­‐pregnancy	  
0	   Dabigatran	  110	  and	  150	  mg	  BID	  
Ezekowitz	  (2007)	   RCT	   18,113	   >75	   AF	  with	  CAD	  and	  at	  least	  1	  of:	  	  -­‐HTN	  w/meds	  -­‐DM	  -­‐HF	  sx	  -­‐LVEF<40%	  	  	  -­‐Previous	  CIA/TIA	  -­‐Age	  >	  75	  
-­‐mitral	  stenosis	  -­‐prosthetic	  heart	  valve	  -­‐planned	  cardioversion	  -­‐MI	  within	  1	  month	  -­‐Recent	  CVA/TIA	  -­‐cardiac	  stent	  <6	  months	  -­‐GFR<30	  mL/min	  -­‐liver	  dysfunction	  -­‐pregnancy	  -­‐investigational	  drug	  use	  <30	  days	  	  
0	   Dabigatran	  50,	  150,	  or	  300	  mg	  alone	  or	  with	  81	  or	  325	  mg	  ASA	  
Wallentin	  (2010)	   RCT	   18,113	   >65	   -­‐Previous	  CVA/TIA	  -­‐LVEF<40%	  -­‐Class	  II	  HF	  sx	  within	  6	  months	  -­‐Age>75	  or	  65-­‐74	  plus	  HTN,	  DM,	  or	  CAD	  
-­‐valvular	  disorder	  -­‐recent	  stroke	  -­‐increased	  hemorrhage	  risk	  -­‐CCl<30	  ml/min	  -­‐liver	  disease	  -­‐pregnancy	  
0	   Dabigatran	  110	  and	  150	  mg	  
Data sources include PubMed and Cochrane databases. Searches were conducted 
using keywords “atrial fibrillation”, “Pradaxa”, and “Dabigatran” between 2011 and 
2012. All articles were published in English between 2007 and 2010 and were selected 
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based on relevance to patients with atrial fibrillation. Statistics used include p-value, 
RRR, ARR, and NNT. Inclusion criteria included previous CVA/TIA, LVEF<40%, age > 
65 and CAD. Exclusion criteria included valvular heart disorders, recent stroke, 
pregnancy, and kidney or liver dysfunction. 
OUTCOMES 
 All outcomes were considered in relationship to patient preservation of neurologic 
function, the POEM that was addressed. Favorable outcomes included decreased rate of 
stroke and systolic embolism as well as decreased rates of intracranial bleeding. 
Unfavorable outcomes included increased rate of stroke, systolic embolism, or 
intracranial bleeding.  
 Stroke was defined as the sudden onset of a focal neurologic deficit in a location 
consistent with the territory of a major cerebral artery and characterized as ischemic, 
hemorrhagic, or unspecified. Intracranial hemorrhage consisted of hemorrhagic stroke 
and subdural or subarachnoid hemorrhage. Systemic embolism was defined as an acute 
vascular occlusion of an extremity or organ, documented by means of imaging, surgery, 
or autopsy1.  
 Outcomes were adjudicated by two investigators who were unaware of the 
treatment assignments. Transient ischemic attacks were further investigated to insure that 
they were not strokes. Questionnaires were routinely administered to participants in order 
to detect possible unreported events1.  
 In the study comparing Dabigatran versus Warfarin in Vitamin K Naïve and 
Experienced patients, patients who are Vitamin K antagonist naïve or Vitamin K 
antagonist experienced were placed on treatments of either D110 (Dabigatran 110 mg) 
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twice per day, D150 (Dabigatran 150 mg) twice per day, or Warfarin titrated to an INR of 
2.0-3.0. Rates of strokes or systolic embolism, intracranial bleeding, or life threatening 
bleeding were compared across these groups4.  
In the study Warfarin vs Dabigatran in patients with Atrial Fibrillation, 
Dabigatran was administered in a blinded fashion in doses of 110 or 150 mg while 
Warfarin was administered in an unblended fashion and titrated to an INR of 2.0-3.0. The 
primary study outcome was stroke, while the primary safety outcome was major 
hemorrhage1.  
 In the study comparing Warfarin and Dabigatran with or without concomitant 
Aspirin, participants were randomized to receive blinded doses of 50, 150, or 300 mg 
Dabigatran twice daily alone or combined with 81- or 325- mg aspirin or open-label 
warfarin administered to achieve an INR of 2 to 3 for 12 weeks3. Rates of bleeding and 
thromboembolic events were recorded and compared between these groups.    
RESULTS 
In the study comparing Warfarin and Dabigatran in Vitamin K Naïve and 
Experienced patients, D110 and D150 were compared to Warfarin in patients that are 
VKA naïve and VKA experienced. In the D110 group, both VKA naïve and experienced 
patients had stroke and systolic embolism rates similar to Warfarin (RR=0.93, 95% CI, 
0.7 to 1.25; P=0.65 and RR= 0.87; 95% CI, 0.66 to 1.15; P=0.32, respectively). However, 
there was a statistically significant decrease in stroke and systolic embolism in patients 
taking D150 versus Warfarin, in both VK naïve (RR=0.63; 95% CI, 0.46 to 0.87; 
P=0.005) and VK experienced patients (RR=0.66; 95% CI, 0.49 to 0.89; P=0.007).  
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In terms of intracranial bleeding, VKA-naïve (RR=0.27, 95% CI, 0.14 to 0.52; P<0.001) 
and VKA-experienced (RR=0.32; 95% CI, 0.18 to 0.56; P<0.001) patients taking D110 
had lower rates of bleeding when compared with patients taking Warfarin.  
 When evaluating treatment effects of D150 versus Warfarin in VKA naïve 
patients, the RRR was 0.366%, ARR was 0.62% and NNT was 161. The D150 VKA 
naïve group had a stroke/systolic embolism rate of 1.07%, while the Warfarin group had 
1.69% of patients experience stroke or systolic embolism. When evaluating the same 
groups for intracranial bleeding rates, 0.33% of the D150 group experienced intracranial 
bleeding, while 0.73 of the Warfarin group experienced intracranial bleeding. The RRR 
was 0.55% ARR was 0.40%, and NNT was 250.  
 Discontinuation of therapy was less common in VKA-experienced patients in the 
D110 and Warfarin groups. The discontinuation rates were similar between VKA naïve 
and experienced patients in the D150 group1.  
Table 2: Stroke, Systolic Embolism, and Bleeding Rates in Ezekowitz et al. 2010 
 D110 D150 Warfarin 
Stroke or systolic 
embolism 
   
VKA naïve  1.57% 1.07% 1.69% 
VKA experienced 1.51% 1.15% 1.74% 
Intracranial 
Bleeding 
   
VKA naïve 0.19% 0.33% 0.73% 
VKA experienced 0.26% 0.32% 0.79% 
 
 In the study comparing Dabigatran vs Warfarin in patients with atrial fibrillation, 
stroke or systolic embolism occurred in 182 patients taking D110 (1.53% per year), 134 
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patients taking D150 (1.11% per year) and 199 patients taking Warfarin (1.69% per year). 
The 150 mg dose of Dabigatran was found to be superior to Warfarin (relative risk, 0.66; 
95% CI, 0.53 to 0.82; P<0.001). Both D110 and D150 were noninferior to Warfarin.  
 Rates of hemorrhagic stroke were 0.38% per year in the Warfarin group. By 
comparison, the Dabigatran 110 mg group rates were 0.12% per year (relative risk with 
Dabigatran, 0.31; 95%CI, 0.17 to 0.56; P<0.001). The Dabigatran 150 mg hemorrhagic 
stroke rate was 0.10% per year (relative risk, 0.26; 95% CI, 0.14 to 0.49; P<0.001).  
 Dabigatran 150 mg reduced the systemic embolism or stroke risk when compared 
with Dabigatran 110 mg. It mainly reduced the risk of thrombus formation and ischemic 
stroke. Hemorrhagic stroke rates were similar in both dose groups. There was not a 
statistically significant difference in death rate between the two groups.  
 Evaluation of treatment effects concerning prevention of stroke and systolic 
embolism in the D150 group versus the Warfarin group showed an RRR of 0.34%, ARR 
of 0.58%, and NNT was 2. When evaluating treatment effects concerning hemorrhagic 
stroke in the same groups, RRR was 0.74%, ARR was 0.28%, and NNT was 357.  
 In terms of adverse events, dyspepsia was the only symptom that was 
significantly more common in subjects receiving Dabigatran in comparison with 
Warfarin. The Warfarin group reported dyspepsia at a rate of 5.8%, while the Dabigatran 
110-mg and 150-mg groups reported dyspepsia at rates of 11.8% and 11.3%, 
respectively. Elevations of LFTs greater than 3 times the upper limit of normal range did 
not occur more frequently in either Dabigatran group than in the Warfarin group3. 
 In the article comparing Warfarin versus Dabigatran with or without concomitant 
Aspirin, patients had a median of 3 risk factors for stroke. The primary outcome in this 
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particular study was major bleeding events. These events were limited to the group 
treated with Dabigatran 300 mg plus Aspirin (4 of 64). There was a statistically 
significant difference between bleeding rates in this group and bleeding rates in the group 
taking Dabigatran 300 mg alone (0 of 105, p<0.02). The frequency of bleeding in patients 
taking Dabigatran 50 mg was significantly less than the group taking Warfain with an 
INR between 2.0-3.0 (p=0.044). There were also differences in bleeding rates between 
the different Dabigatran doses. In the Dabigatran 300 mg group, 37 of 169 had bleeding 
events whereas in the 50 mg group, 7 of 107 had bleeding events (p=0.0002). In the 
Dabigatran 150 mg group, 30 of 169 had bleeding events when compared with 7 of 107 
in the 50 mg group (p=0.01)3.  
 Two patients had systemic thromboembolic events in this study. Both of the 
participants received the 50 mg dose of Dabigatran3.   
 When considering the treatment effects of Dabigatran 150 mg alone versus 
Warfarin alone, the RRR was 0.12%, ARR was 2.1% and NNT was 48. In the 150 mg 
Dabigatran group, 15% of patients had either bleeding or thromboembolic events. In the 
Warfarin group, 17.1% experienced either one of the major outcomes in this study.   
Table 3: Rates of bleeding and thromboembolic events in patients receiving Dabigatran 
alone or combined with aspirin versus Warfarin alone.  
Dabigatran 
dose BID 
Aspirin dose #pts Bleeding 
events (major) 
Thromboembolic 
events 
Total 
50 0 59 0 0 2 (2.4%) 
50 81 21 0 1 (4.8%) 2 (9.5%) 
50 325 27 0 1 (3.7%) 3 (11.1%) 
150 0 100 0 9 (9%) 15 (15%) 
150 81 36 0 2 (5.6%) 8 (22.2%) 
150 325 33 0 2 (6.1%) 7 (21.2%) 
300 0 105 0 6 (5.7%) 14 (32.4%) 
300 81 34 1 (2.9%) 5 (14.7) 11 (32.4%) 
300 325 30 3 (10%) 6 (20%) 14 (46.7%) 
Warfarin 0 70 0 4 (5.7%) 12 (17.1%) 
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 More patients discontinued treatment in the Dabigatran group than in the 
Warfarin group due to adverse events. The most common adverse event reported was 
gastrointestinal discomfort such as nausea, vomiting, or diarrhea while taking Dabigatran. 
Most of the adverse symptoms were mild and did not require discontinuation of 
treatment3.   
DISCUSSION 
 One of the most serious complications of Warfarin therapy has been an increased 
risk for intracranial hemorrhage, especially hemorrhagic stroke. Dabigatran offers a two-
thirds reduction in risk for intracranial hemorrhage, without increasing the risk for 
thromboembolic events1.  
A factor contributing to the benefits of Dabigatran may be the twice-daily dosing 
and shorter half-life. This enables the drug to have more stable anticoagulant effects 
throughout the day. This offers a large benefit in comparison to the difficult to control 
anticoagulant effects of Warfarin. Warfarin broadly inhibits coagulation, inhibiting 
factors II, VII, IX, and X as well as protein C and S. By contrast, Dabigatran selectively 
inhibits thrombin, which may enable the drug to prevent thrombosis while maintaining 
other aspects of coagulation and potentially preventing major bleeding1.  
A limiting factor for patients with atrial fibrillation is the cost of Dabigatran 
compared to the cost of Warfarin. Because the majority of patients treated for atrial 
fibrillation are >65 years old, the majority of them receive Medicare benefits. When 
Dabigatran was first released, the cost for Medicare patients was around $250 per month, 
while the cost of Warfarin was about $4 per month. Since its release, Dabigatran is now 
covered under Medicare Part D and costs $25-$40 per month. While it remains more 
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expensive than Warfarin, it is now considered to be much more affordable and patients 
are able to weigh the increased cost against potential other benefits such as decreased 
stroke risk and the lack of serum monitoring.   
 A possible limitation of this study is the open-label administration of Warfarin, 
preventing it from being completely double-blinded. This was necessitated by the INR 
monitoring associated with Warfarin treatment. However, the evaluation of outcome 
events remained blinded. Therefore, the risk for bias was significantly reduced.    
CONCLUSIONS 
 Based on these three studies, it is concluded that Dabigatran is superior to 
Warfarin in the treatment of patients with atrial fibrillation. Dabigatran 110-mg and 150-
mg groups consistently had lower rates of stroke and intracranial hemorrhage when 
compared with the Warfarin group. Therefore, neurologic function was preserved more 
frequently in the Dabigatran groups. Future research is warranted to evaluate whether or 
not Dabigatran is superior to Warfarin in preventing deep venous thrombosis (DVT) and 
subsequent pulmonary embolism (PE). To date, Warfarin remains the treatment of choice 
because Dabigatran does not have this indication for treatment. 
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